Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

NORML

FEBRUARY 1, 2019

According to data compiled by the US Centers for Disease Control, the drug was attributed to over 11,500 overdose deaths in 2017. In the first study , Canadian researchers assessed the relationship between cannabis and benzodiazepines in a cohort of 146 patients enrolled in the nation’s medical marijuana access program.

Patients 245

Patients Chronic Pain Therapy Data 245

NORML

JUNE 10, 2020

The agency’s call for comments, initially posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 246

Chronic Pain Therapy Patients Topical 246

Cannabis Law Report

JANUARY 6, 2022

This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy. The FDA will likely refer to this data as it considers formal approval for psilocybin therapy and products.

Access 52

Access Patients Research and Development Treatment 52

NORML

NOVEMBER 25, 2019

Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One.

Chronic Pain 282

Chronic Pain Patients Therapy Data 282

Cannabis Law Report

SEPTEMBER 28, 2021

The TGA has approved the use of MDMA and Psilocybin to treat mental illness in Australia by qualified medical professionals under a special access scheme. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data. If you withdraw no data from your response will be saved. Participant Information Sheet.

Therapy 52

Therapy Medicine Data Collective 52

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Veriheal

NOVEMBER 30, 2021

Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Research and Development 96

Research and Development Therapy Data Treatment 96

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. and his conclusion.

Research and Development 52

Research and Development Therapy Access Data 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

JULY 22, 2021

A master distribution agreement has been signed with My Green Planet, a leading global agricultural supply group, giving Sporeo access to approximately 7,000 retailers across North America, Australia, and Europe. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

eCommerce 105

eCommerce Therapy Media Access 105

Veriheal

OCTOBER 20, 2021

Veriheal does not support illegally consuming alternative therapeutic substances but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting psychedelic therapy. A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. RoC also works to increase patients’ access to medical cannabis by helping U.S.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Veriheal

AUGUST 11, 2023

The Psilocybin Data Act ’s new-found life is due in large part to shifts in the Pennsylvania House’s balance after the recent election. They emphasize the need for diverse representation in research and equitable access to psychedelic-assisted therapy. Victor Cabral, a social worker, had one possible solution.

Research and Development 52

Research and Development Advocacy Therapy Access 52

Cannabis Law Report

MARCH 9, 2022

“These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies.” ” About Numinus.

Research and Development 52

Research and Development Therapy Access Medicine 52

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Rahn & Associates announced today that it launched new risk management solutions for the burgeoning psychedelic medicinal industry.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

NOVEMBER 3, 2021

Khiron in the United Kingdom The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. Both virtual and in-person appointments can be made via the website www.zereniaclinic.co.uk.

Therapy 52

Therapy Access Patients Treatment 52

SpeedWeed

MAY 22, 2021

For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. . This work builds capacity to deliver quality, accessible care to patients, pending approval of MDMA-assisted therapy as a legal prescription treatment.”. View original article.

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Canna Law Blog

DECEMBER 16, 2021

Psilocybin therapy is a breakthrough avenue for providing people with treatment for these ailments. Data from the RAND Corporation show that 8,000 New York veterans from the Wars in Iraq and Afghanistan suffer from PTSD. The FDA recognizes psilocybin therapy as substantially better than present treatment options.

Legislation 96

Legislation Treatment Therapy Conditions 96

Cannabis Law Report

APRIL 12, 2019

I am also prescribed pharmacological and non-pharmacological therapies and try to keep a base of exercise and good nutrition. CFAMM’s goal is to support medical cannabis patients, improve their outcomes and enable them to obtain fair and safe access to their medication. million medical cannabis patients in Canada. About CFAMM.

Access 45

Access Patients Marijuana Medicine 45

Cannabis Law Report

JUNE 8, 2022

Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. MDMA-assisted therapy, a novel treatment for PTSD with FDA breakthrough therapy designation, is on track for NDA submission in 2023 pending results of the confirmatory Phase 3 trial. He holds a Ph.D.

Therapy 52

Therapy Treatment Access Patients 52

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. “Numinus is glad to see Health Canada committing to broadened mental healthcare access, starting with those in most need,” said Payton Nyquvest, CEO of Numinus.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

AUGUST 2, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.

Research and Development 98

Research and Development Therapy Collective Treatment 98

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

United Patients Group

AUGUST 16, 2023

Accessibility and Inclusivity Building an inclusive and accessible workplace is the first step in improving the daily lives of people with disabilities. Accessibility involves digital areas and data in addition to physical infrastructure.

Advocacy 52

Advocacy Education Access Environment 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. Drug Enforcement Agency (DEA). Is the future exciting?

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Project CBD

AUGUST 6, 2019

Over 200 scientists from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data. Results highlight the need for expanded patient access to CBD products.”. CBD for hypertension.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. 10] In the meantime, FDA has approved some requests for compassionate use. [11].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. Using data from the Therapeutic Goods Administration (TGA) – Australia’s Special Access Scheme B, the researchers found the other two top reasons for prescriptions were pain and sleep disorders. Here’s the Uni of Sydney press release. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52